Department of Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, California, USA.
CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):177-184. doi: 10.1002/psp4.12499. Epub 2020 Mar 12.
Progression-free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum-resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.
无进展生存期(PFS)已越来越多地被用作早期临床开发的主要终点。本研究的目的是开发一种模型,该模型可以联合建模靶病灶动力学和非靶病灶进展风险,以预测 PFS。该模型是基于包含四种不同治疗方法和广泛剂量水平的铂类耐药卵巢癌数据集开发的。靶病灶进展是基于实体瘤反应评估标准(RECIST)标准从肿瘤生长动力学中推导出来的。非靶病灶进展的风险与靶病灶肿瘤大小随时间的一阶导数相关。PFS 时间由首次发生的事件、靶病灶进展或非靶病灶进展决定。最终的联合模型不仅可以捕捉靶病灶肿瘤生长动力学,还可以很好地预测 PFS。类似的方法可能有潜力用于预测未来肿瘤学研究中的 PFS。